La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Eris Lifesciences Bilan de santé
Santé financière contrôle des critères 2/6
Eris Lifesciences possède un total de capitaux propres de ₹32.2B et une dette totale de ₹27.8B, ce qui porte son ratio d'endettement à 86.3%. Son actif total et son passif total sont ₹70.5B et de ₹38.3B. L'EBIT de Eris Lifesciences est ₹5.4B ce qui fait que son ratio de couverture des intérêts 4.2. Elle dispose de liquidités et de placements à court terme de ₹14.0B.
Informations clés
86.3%
Ratio d'endettement
₹27.81b
Dette
| Ratio de couverture des intérêts | 4.2x |
| Argent liquide | ₹14.01b |
| Fonds propres | ₹32.22b |
| Total du passif | ₹38.27b |
| Total des actifs | ₹70.49b |
Mises à jour récentes de la santé financière
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20Recent updates
Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)
Jul 13Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 10Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year
Nov 23Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?
Oct 22How Does Eris Lifesciences' (NSE:ERIS) CEO Salary Compare to Peers?
Oct 01How Much Are Eris Lifesciences Limited (NSE:ERIS) Insiders Taking Off The Table?
Sep 14Analyse de la situation financière
Passif à court terme: Les actifs à court terme de ERIS ( ₹23.0B ) ne couvrent pas ses passifs à court terme ( ₹25.3B ).
Passif à long terme: Les actifs à court terme de ERIS ( ₹23.0B ) dépassent ses passifs à long terme ( ₹12.9B ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de ERIS ( 42.8% ) est considéré comme élevé.
Réduire la dette: Le ratio d'endettement de ERIS est passé de 15.1% à 86.3% au cours des 5 dernières années.
Couverture de la dette: La dette de ERIS n'est pas bien couverte par le flux de trésorerie opérationnel ( 17.5% ).
Couverture des intérêts: Les paiements d'intérêts de ERIS sur sa dette sont bien couverts par l'EBIT ( 4.2 x couverture).